Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 8, Pages 1922
Publisher
MDPI AG
Online
2021-04-16
DOI
10.3390/cancers13081922
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
- (2020) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
- (2020) Sai Arun Batra et al. Cancer Immunology Research
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis
- (2020) Hidetaka Yasuoka et al. Scientific Reports
- Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
- (2020) Yung-Jue Bang et al. EUROPEAN JOURNAL OF CANCER
- PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression
- (2020) Jin Yun et al. IMMUNOLOGIC RESEARCH
- Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice
- (2020) Xuhua Duan et al. CELL CYCLE
- Combination therapy with anti‐T‐cell immunoglobulin and mucin‐domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma
- (2020) Kyoung‐Jin Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
- (2019) Ahmed Omar Kaseb et al. JOURNAL OF CLINICAL ONCOLOGY
- Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
- (2019) Ying Zhu et al. GUT
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
- (2019) C Luchini et al. ANNALS OF ONCOLOGY
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
- (2019) Laura M. McLane et al. Annual Review of Immunology
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
- (2019) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma
- (2019) Sandrine Faivre et al. LIVER INTERNATIONAL
- Immune checkpoint inhibitors for hepatocellular carcinoma
- (2019) Imane El Dika et al. CANCER
- 4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8 + T cells in Hepatocellular Carcinoma
- (2019) Hyung‐Don Kim et al. HEPATOLOGY
- TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma
- (2019) Xiaochen Wang et al. JOURNAL OF HEPATOLOGY
- Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade
- (2019) Rohit R. Jadhav et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
- (2019) Ahmed Omar Kaseb et al. Cancer Immunology Research
- M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
- (2019) Zhaoyun Zong et al. Frontiers in Immunology
- Modulation of asymmetric cell division as a mechanism to boost CD8+ T cell memory
- (2019) Mariana Borsa et al. Science Immunology
- Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC
- (2019) Yonghui Zhang et al. MOLECULAR THERAPY
- Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma
- (2019) Catrin Tauber et al. Oncotarget
- CD8+CXCR5+T cells infiltrating hepatocellular carcinomas are activated and predictive of a better prognosis
- (2019) Linsen Ye et al. Aging-US
- Metabolic Consequences of T-cell Costimulation in Anticancer Immunity
- (2019) Alvaro Teijeira et al. Cancer Immunology Research
- Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
- (2019) Marc Hilmi et al. Journal for ImmunoTherapy of Cancer
- PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
- (2019) Jiaqiang Ma et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
- (2018) Chao-Qun Liu et al. BRITISH JOURNAL OF CANCER
- TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression
- (2018) Jiawei Huang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
- (2018) Chun Jye Lim et al. GUT
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- The function and dysfunction of memory CD8+ T cells in tumor immunity
- (2018) James L. Reading et al. IMMUNOLOGICAL REVIEWS
- A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
- (2018) Masafumi Ikeda et al. INVESTIGATIONAL NEW DRUGS
- 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
- (2018) Ashley V. Menk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients
- (2018) Boyang Chang et al. LIVER INTERNATIONAL
- Superagonist IL-15-armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
- (2018) Stacy J. Kowalsky et al. MOLECULAR THERAPY
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Asymmetric PI3K Activity in Lymphocytes Organized by a PI3K-Mediated Polarity Pathway
- (2018) Yen-Hua Chen et al. Cell Reports
- Epigenetic Maintenance of Acquired Gene Expression Programs during Memory CD8 T Cell Homeostasis
- (2018) Hossam A. Abdelsamed et al. Frontiers in Immunology
- Characteristics of immune response to tumor-associated antigens and immune cell profile in hepatocellular carcinoma patients
- (2018) Yuki Inada et al. HEPATOLOGY
- IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
- (2018) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver
- (2018) Itziar Otano et al. MOLECULAR THERAPY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
- (2018) T. Mocan et al. Clinical & Translational Oncology
- Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
- (2018) Hyung-Don Kim et al. GASTROENTEROLOGY
- Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
- (2018) Yu-Yang Lin et al. SEMINARS IN LIVER DISEASE
- Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
- (2018) Xingliang Guo et al. Frontiers in Pharmacology
- Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives
- (2017) Gaël S. Roth et al. EUROPEAN JOURNAL OF CANCER
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- CXCR5 + CD8 + T cells could induce the death of tumor cells in HBV-related hepatocellular carcinoma
- (2017) Yun Jin et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma
- (2017) Chun-yu Huang et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
- (2017) Valerie Chew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- The diagnosis and treatment of hepatocellular carcinoma
- (2017) Justin Hartke et al. SEMINARS IN DIAGNOSTIC PATHOLOGY
- Differential Location and Distribution of Hepatic Immune Cells
- (2017) Maria Freitas-Lopes et al. Cells
- Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming
- (2016) Michael D. Buck et al. CELL
- Reversing T-cell Dysfunction and Exhaustion in Cancer
- (2016) H. M. Zarour CLINICAL CANCER RESEARCH
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Specific CD8+T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis
- (2016) Elia Moreno-Cubero et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
- (2016) Xian-Shu Gao et al. OncoTargets and Therapy
- Anabolism-Associated Mitochondrial Stasis Driving Lymphocyte Differentiation over Self-Renewal
- (2016) William C. Adams et al. Cell Reports
- CD8 + T Lymphocyte Self-Renewal during Effector Cell Determination
- (2016) Wen-Hsuan W. Lin et al. Cell Reports
- Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
- (2016) A. Gabrielson et al. Cancer Immunology Research
- Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
- (2016) Massimiliano Berretta et al. Frontiers in Pharmacology
- IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
- (2015) K. Pilipow et al. CANCER RESEARCH
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- How Do Cytotoxic Lymphocytes Kill Cancer Cells?
- (2015) L. Martinez-Lostao et al. CLINICAL CANCER RESEARCH
- T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice
- (2015) Christina Dargel et al. GASTROENTEROLOGY
- Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
- (2015) Marta Garnelo et al. GUT
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
- (2015) Lee B. Rivera et al. Cell Reports
- Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model
- (2014) Hossein Panjideh et al. INTERNATIONAL JOURNAL OF CANCER
- Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
- (2014) YU SAWADA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses
- (2014) Liang Cheng et al. JOURNAL OF HEPATOLOGY
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
- (2014) B. Farsaci et al. Cancer Immunology Research
- Tumor-associated antigen specific CD8+T cells in hepatocellular carcinoma – a promising target for immunotherapy
- (2014) Nathalie Schmidt et al. OncoImmunology
- Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
- (2013) A. Morales-Kastresana et al. CLINICAL CANCER RESEARCH
- Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
- (2013) Martin Franz Sprinzl et al. HEPATOLOGY
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma
- (2013) Tobias Flecken et al. HEPATOLOGY
- A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocelluar carcinoma
- (2013) Xiaozhou Yu et al. JOURNAL OF CLINICAL IMMUNOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner
- (2013) R. B. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modulation of Immunity by Antiangiogenic Molecules in Cancer
- (2012) Magali Terme et al. Clinical & Developmental Immunology
- Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma
- (2012) Eishiro Mizukoshi et al. HEPATOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection
- (2012) M. A. Paley et al. SCIENCE
- Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory Development
- (2011) Gerritje J.W. van der Windt et al. IMMUNITY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
- (2011) Tae-Won Kang et al. NATURE
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines
- (2010) Adam J. Gehring et al. JOURNAL OF HEPATOLOGY
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma
- (2009) Adam J. Gehring et al. GASTROENTEROLOGY
- Chronically inflamed livers up-regulate expression of inhibitory B7 family members
- (2009) Rachel Kassel et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started